Entities / Company
UniQure (Netherlands).
company in Amsterdam, Netherlands
- Reports this week
- 0
- Active events
- 1
- Connections
- 33
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
UniQure partnered with the FDA regarding AMT-130, an experimental gene therapy for Huntington's disease, while ClearPoint provided infusion disposables.Speculative1 report
-
UniQure is advancing its ALS programs, including AMT-130 targeting Huntington’s disease, with FDA alignment supporting BLA submission.Some support2 reports
-
UniQure presented data on inborn errors of metabolism at the International Congress of Inborn Errors of Metabolism.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around UniQure (Netherlands) this week
News at the entities that move UniQure (Netherlands) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves UniQure (Netherlands)
Connections
The 2 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.History
Events by the month they beganJune 2026
4 events- Trump pledged to unleash American oil and gas and advised investors on market timing in August 2025.
- UniQure partnered with the FDA regarding AMT-130, an experimental gene therapy for Huntington's disease, while ClearPoint provided infusion disposables.
- UniQure is advancing its ALS programs, including AMT-130 targeting Huntington’s disease, with FDA alignment supporting BLA submission.
- UniQure presented data on inborn errors of metabolism at the International Congress of Inborn Errors of Metabolism.